| Current Price | $21.48 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $21.43 | P/E Ratio | -2.48 |
| Prev. Close | $21.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $20.75 - $21.67 | Volume | 695,791 |
| 52-Wk Range | $17.53 - $59.84 | Avg. Daily Vol. | 1,436,877 |
| Current Price | $21.48 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $21.43 | P/E Ratio | -2.48 |
| Prev. Close | $21.48 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $20.75 - $21.67 | Volume | 695,791 |
| 52-Wk Range | $17.53 - $59.84 | Avg. Daily Vol. | 1,436,877 |
The best Bull and Bear pitches based on recency and number of recommendations.
As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating 2 patients whose baseline data was faulty) in the… More
Read the most recent pitches from players about PTCT.
Recs
TMFBiologyFool
(38.14)
Submitted: 6/19/2018 5:31:18 PM :
Start Price:
$35.00
NASDAQ:PTCT Score:
-103.13
Overreaction to SRPT gene therapy data.
Recs
MarkBiotech
(< 20)
Submitted: 3/7/2018 4:30:35 PM :
Start Price:
$27.90
NASDAQ:PTCT Score:
-91.08
the quick uptake and strong launch of SRPT's Exondy's has shown us how large of a need their is for DMD patients. Despite the public backlash on emflaza's pricing, its launch still continues to be very strong.. Also ataluren's EU sales are progessing nicely.. the eventual approval(despite CRL) for ataluren in the US should give PTCT a good boost in future value.. Guidance for 2018 stands at 260-295M(VS 300M for srpt).. that puts PTCT valuation at 4x 2018 sales which is considered VERY CHEAP.. This valuation is also undermining RG7916 in SMA which has shown robust preliminary data. i could see PTCT double in the near future due to its low valuation.. PT- 60
Recs
zzlangerhans
(98.81)
Submitted: 5/26/2016 5:14:18 PM :
Start Price:
$7.88
NASDAQ:PTCT Score:
-55.60
PTC continues to have its ups and downs since the February crash but I share the view of the FDA that there is no evidence Translarna is effective. I think there's a good chance that CHMP will revoke the conditional approval within the next few months, but the chance that they do not is enough to keep me from shorting the stock. CHMP seems to have a somewhat different mentality about placebos than the FDA. Regardless, one day the truth will finally be apparent to all and PTC will stop diverting valuable and limited resources away from treatments that might actually work.
Find the members with the highest scoring picks in PTCT.
portefeuille2 (97.67) Score: +422.22
The Score Leader is the player with the highest score across all their picks in PTCT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| helicopterfool | 77.20 | 6/24/2015 |
|
5Y | $51.43 | -58.23% | +115.67% | +173.90 | 0 Comment | |
| Tqluu | 74.24 | 5/18/2015 |
|
5Y | $52.43 | -59.03% | +114.13% | +173.17 | 0 Comment | |
| SimonSaysSell | 98.80 | 1/27/2014 |
|
NS | $26.63 | -19.34% | +153.81% | +173.15 | 0 Comment | |
| thebeef41 | 47.94 | 10/2/2013 |
|
1Y | $20.71 | +3.72% | +169.34% | +165.62 | 0 Comment | |
| pro64grammer | 24.48 | 5/23/2014 |
|
5Y | $23.40 | -8.20% | +138.87% | +147.07 | 0 Comment | |
| stainsolution | < 20 | 3/1/2016 |
|
5Y | $5.70 | +276.84% | +130.34% | +146.50 | 0 Comment | |
| noataluren | < 20 | 5/28/2014 |
|
1Y | $23.38 | -8.13% | +137.28% | +145.41 | 1 Comment | |
| joe508mama | 29.82 | 5/23/2014 |
|
5Y | $22.54 | -4.71% | +139.00% | +143.71 | 0 Comment | |
| HoldThatWinner | 27.38 | 5/27/2014 |
|
1Y | $20.23 | +6.18% | +137.89% | +131.71 | 0 Comment | |
| portefeuille | 97.82 |
|
|
NS | $6.42 | +234.58% | +131.92% | +102.65 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
